{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3"}]}],"title":"Subject MM-91"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6"}]}],"title":"Subject MM-92"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4"}]}],"title":"Subject MM-95"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6"}]}],"title":"Subject MM-96"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2"}]}],"title":"Subject MM-98"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9"}]}],"title":"Subject MM-99"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6"}]}],"title":"Subject MM-109"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2"}]}],"title":"Subject MM-111"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Concentration of panobinostat and dexamethasone in combination leading to 90% growth inhibition of multiple myeloma cells in-vitro. The combination index (CI) is calculated using formula: CI = (\\[D1\\] in the combination / \\[D1\\] alone) + (\\[D2\\] in the combination / \\[D2\\] alone). Key: CI = 1 no synergy; CI\\<1 synergy; CI\\>1 antagonism.","groups":[{"description":"Patients undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay. Regardless of assay results, patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19, and carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone"}],"paramType":"NUMBER","populationDescription":"CI score was not reported for subject MM-82","reportingStatus":"POSTED","timeFrame":"At baseline","title":"Synergy of Panobinostat and Dexamethasone in Combination, Per Subject","type":"PRIMARY","unitOfMeasure":"CI score"}